Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
about
T cell receptor mimic antibodies for cancer therapyMesothelin-Targeted CARs: Driving T Cells to Solid TumorsLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesThe role of host genetic factors in respiratory tract infectious diseases: systematic review, meta-analyses and field synopsisTargeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cellsUncovering Direct Targets of MiR-19a Involved in Lung Cancer Progression.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma.Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradientAn allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer.Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients.Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection.Adoptive immunotherapy for cancer.CAR T-cell immunotherapy: The path from the by-road to the freeway?Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?
P2860
Q26768271-FCA0217B-329C-4A9F-971D-B3EF18E703B7Q26778759-3418986B-6160-44D1-A321-5367C1A29E8AQ28395597-23434226-B82F-43F1-AFC2-3BFD47ED34EAQ28608163-FE20B219-5026-4650-9FC5-299092BBE766Q33889144-8E53D457-31D1-47FC-BDB2-C7087EC16F0EQ35773305-C7D76278-C1B8-4B85-B669-34724D36F1DFQ35980893-2D67928F-7CFC-4BCA-9770-D393DC96D6B2Q36413088-2B054A9F-84FF-4771-8630-DBDF1938516AQ36811526-88E102AF-B6D6-465D-B277-B3971AA3A375Q37488222-9F8E0F0C-6850-4ABC-A33C-8779EA158F8CQ37492906-6AA2AF14-2532-4230-9B28-78A1D9444C4AQ38144256-09C4D00A-E1A4-4892-BC09-C3B1B411716CQ38170496-01819B5E-3FA5-42DD-9F67-7FC83C0694DFQ38632105-632C37C0-5087-43F5-BAE2-3E83F98F3304Q41143349-4B4C7F1F-8A54-4499-9FA8-4DCFBFEC8C1FQ47193084-ADB7A076-BDAA-463B-8797-81572DDD225BQ47285613-41CC5C2A-F407-4E8A-B691-E3FD45440560
P2860
Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Co-introduced functional CCR2 ...... WT1-specific T-cell receptor.
@ast
Co-introduced functional CCR2 ...... WT1-specific T-cell receptor.
@en
type
label
Co-introduced functional CCR2 ...... WT1-specific T-cell receptor.
@ast
Co-introduced functional CCR2 ...... WT1-specific T-cell receptor.
@en
prefLabel
Co-introduced functional CCR2 ...... WT1-specific T-cell receptor.
@ast
Co-introduced functional CCR2 ...... WT1-specific T-cell receptor.
@en
P2093
P2860
P1433
P1476
Co-introduced functional CCR2 ...... s WT1-specific T-cell receptor
@en
P2093
Hiroaki Asai
Hirofumi Inoue
Hiroshi Fujiwara
Junichi Mineno
Kiyotaka Kuzushima
Kozo Nagai
Masaki Yasukawa
Sachiko Okamoto
Toshiki Ochi
P2860
P304
P356
10.1371/JOURNAL.PONE.0056820
P407
P577
2013-02-18T00:00:00Z